Showing 5601-5610 of 9878 results for "".
- Regular Moisturizer Use May Reduce Signs of Aging Skin, Plus More Research from Estée Lauderhttps://practicaldermatology.com/news/regular-moisturizer-use-may-reduce-signs-of-aging-skin-on-the-face-skin-aging-plus-more-wcd-presented-research-from-estee-lauder/2461846/Regular use of moisturizer can mitigate skin aging, according to research presented by The Estée Lauder Companies Inc. at the 25th World Congress of Dermatology in Singapore. In an evaluator-blinded, randomized, 6-month longitudinal study of 160 women, a
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, sp
- WCD News: Spesolimab Prevents GPP Flareshttps://practicaldermatology.com/news/wcd-news-spesolimab-prevents-gpp-flares/2461841/Spesolimab reduced the risk of generalized pustular psoriasis (GPP) flares flares by 84% over 48 weeks compared to placebo, according to late-breaking data from the EFFISAYIL™ 2 trial presebted at the at the 25th World Congress of Dermatology (WCD) in Singapore. Fur
- Dr. Uri Geiger Named Chairman of its Board of Directors at STRATA Skin Scienceshttps://practicaldermatology.com/news/dr-uri-geiger-named-chairman-of-its-board-of-directors-at-strata-skin-sciences/2461837/Uri Geiger, PhD, is the new Chairman of the Board of Directors at STRATA Skin Sciences. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year.
- News Your Patients Can Use: AAD Offers Sun Protection Counsel in Advance of Independence Day Holiday Weekendhttps://practicaldermatology.com/news/news-your-patients-can-use-aad-offers-sun-protection-counsel-in-advance-of-independence-day-holiday-weekend/2461819/Remind your patients to use sunscreen on the July 4th weekend and on the days, weeks, and months that follow. A recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults revealed that one-third of American parents reported having a child who
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on